# DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

> **NCT04811443** · — · UNKNOWN · sponsor: **Biocad** · enrollment: 500 (estimated)

## Conditions studied

- Patients With Solid Tumours Who Receive Myelosupressive Therapy

## Interventions

- **DRUG:** Empegfilgrastim

## Key facts

- **NCT ID:** NCT04811443
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-12
- **Primary completion:** 2022-06-12
- **Final completion:** 2022-06-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04811443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04811443, "DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04811443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*